GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » 3-Year FCF Growth Rate

Nuvation Bio (Nuvation Bio) 3-Year FCF Growth Rate : -22.80% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio 3-Year FCF Growth Rate?

Nuvation Bio's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -22.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 4 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Nuvation Bio was -22.80% per year. The lowest was -22.80% per year. And the median was -22.80% per year.


Competitive Comparison of Nuvation Bio's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Nuvation Bio's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's 3-Year FCF Growth Rate falls into.



Nuvation Bio 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Nuvation Bio  (NYSE:NUVB.WS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Nuvation Bio 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Traded in Other Exchanges
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).